This pancreatic cancer treatment is on track for ‘one of the best drug launches of all time’ Revolution Medicines’ brand-new treatment brought in far higher sales than expected in its first few weeks on the market A brand-new treatment for pancreatic cancer may be the best oncology launch of all time. Revolution Medicines announced Wednesday evening that Rasonque, its pancreatic cancer drug that received approval from the Food and Drug Administration in late August, brought in $198 million in sales in the third quarter, putting it on track for $527 million in sales in the fourth quarter and $3.1 billion in sales next year, according to Jefferies. The FactSet estimate for the third quarter was $24.9 million.
Jaimy Lee is a healthcare editor and reporter for MarketWatch. She is based in New York.
Extract — continue reading at the source.
